XOMA 052 reduces adverse consequences that lead to development of congestive heart failure (News-Medical-Net)
March 15th, 2010
XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).
Original post by macular degeneration – Google News
(click on the author/publication link above to see full post)